Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) just unveiled an announcement.
Shanghai Fosun Pharmaceutical has announced several key leadership appointments and reappointments effective from June 24, 2025. The company has reappointed Mr. Chen Yuqing as chairman, Ms. Guan Xiaohui as co-chairman, and Mr. Wen Deyong as vice chairman. Additionally, Mr. Liu Yi has been appointed as the new CEO and president, while Ms. Li Jing, Mr. Xingli Wang, and Mr. Wenjie Zhang have been named co-presidents. These changes are expected to strengthen the company’s strategic direction and governance, potentially impacting its market positioning and stakeholder relations positively.
The most recent analyst rating on (HK:2196) stock is a Hold with a HK$17.20 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock limited company incorporated in China, operating in the pharmaceutical industry. The company focuses on the development, manufacturing, and sale of pharmaceutical products and medical devices, with a market presence both domestically and internationally.
Average Trading Volume: 7,025,116
Technical Sentiment Signal: Buy
Current Market Cap: HK$65.06B
For an in-depth examination of 2196 stock, go to TipRanks’ Overview page.